Heike Froehlich, Dr.
AbbVie Deutschland GmbH & Co. KG
Mainzer Straße 81
Wiesbaden
Germany
65189
Papers:
BUDGET IMPACT ANALYSIS FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C IN GERMANY WITH OMBITASVIR / PARITAPREVIR / RITONAVIR AND DASABUVIR